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DetoxiﬁcationThe receptor for advanced glycation end products (RAGE) is a multi-ligand receptor. Alternative splicing and
enzymatic shedding produce soluble forms that protect against damage by ligands including Advanced Glycation
End products (AGEs). A link between RAGE and oxygen levels is evident from studies showing RAGE-mediated
injury following hyperoxia. The effect of hypoxia on pulmonary RAGE expression and circulating sRAGE levels
is however unknown. Therefore mice were exposed to chronic hypoxia for 21 d and expression of RAGE,
sheddases in lungs and circulating sRAGE were determined. In addition, accumulation of AGEs in lungs and
expression of the AGE detoxifying enzyme GLO1 and receptors were evaluated.
In lung tissue gene expression of total RAGE, variants 1 and 3were elevated inmice exposed to hypoxia, whereas
mRAGE and sRAGE protein levels were decreased. In the hypoxic group plasma sRAGE levels were enhanced.
Although the levels of pro-ADAM10 were elevated in lungs of hypoxia exposed mice, the relative amount of
the active form was decreased and gelatinase activity unaffected. In the lungs, the RAGE ligand HMGB1 was
decreased and of the AGEs, only LW-1 was increased by chronic hypoxia. Gene expression of AGE receptors
2 and 3 was signiﬁcantly upregulated.
Chronic hypoxia is associated with downregulation of pulmonary RAGE protein levels, but a relative increase in
sRAGE. These alterations might be part of the adaptive and protective response mechanism to chronic hypoxia
and are not associated with AGE formation except for the ﬂuorophore LW-1 which emerges as a novel marker
of tissue hypoxia.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The receptor for advanced glycation end products (RAGE) is a
transmembrane, multi-ligand, pattern-recognition receptor belonging
to the immunoglobulin super family of cell surface receptors [1,2]. The
wide variety of ligands include pathogen and damage-associated
molecular patternmolecules (PAMPs andDAMPs) such as highmobility
group B1 (HMGB1) and advanced glycation end products (AGEs) after
which it was named [3]. AGEs are a class of compounds formed by
non-enzymatic glycation and oxidation of proteins and lipids. Binding
of AGEs and other ligands to RAGE causes activation of downstream
signaling pathways, leading to the activation of the pro-inﬂammatory
transcription factor nuclear factor kappa B (NF-κB) [4]. Ligand accumu-
lation and engagement in turn upregulates RAGE expression [5].
Structurally RAGE consists of an extracellular, a transmembrane, and
cytosolic domain (mRAGE). In addition, soluble forms exist,which act as
decoy receptors since they display similar afﬁnity for ligands, anddical Center, Dept. Respiratory
rlands. Tel.: +31 43 3882270;
.L. Reynaert).thereby limit their availability tomRAGE [6]. Soluble forms are generat-
ed by two distinct mechanisms. Firstly, by alternative splicing of the
AGER gene, which leads to the formation of endogenous soluble RAGE
(esRAGE) [7,8]. Secondly, ectodomain shedding ofmRAGE by sheddases
like Disintegrin and Metalloproteinase domain Containing protein-10
(ADAM10) and matrix metalloproteinase 9 (MMP9) generates soluble
RAGE (sRAGE), which lacks both the transmembrane and cytosolic
domain [6,9].
RAGE is highly expressed in the mature lung by type I pneumocytes
(ATI) compared to other lung cells and other tissues [10]. As a pattern
recognition receptor, RAGE has been implicated in the pathogenesis of
multiple (chronic) pulmonary inﬂammatory conditions such as chronic
obstructive pulmonary disease (COPD), acute lung injury (ALI)/adult
respiratory distress syndrome (ARDS) and lung cancer [11–16]. Speciﬁc
associations with lung development, immune responses, inﬂammation
and tissue remodeling have been described. For instance embryonic
overexpression of RAGE in mice leads to under development of the
lungs, while overexpression in adult animals was shown to lead to
airspace enlargement and a pro-inﬂammatory state [17,18].
In lungs of healthy smokers, patientswith COPD andmice chronically
exposed to cigarette smoke, increased expression of RAGE was shown
[19–21]. Bronchoalveolar lavage ﬂuid (BALF) levels of sRAGE were also
Table 1
Primer sequences used.
Gene name Forward 5′–3′ Reverse 3′–5′
Mouse
VEGF-A CTGTACCTCCACCATGCCAAGT TCGCTGGTAGACATCCATGAACT
VEGF-B TGCCCATGAGTTCCATGC CCCAGTTTGATGGCCCCA
VEGF-C TTTAAGGAAGCACTTCTGTG
TGT
GTAAAAACAAACTTTTCCCTAA
TTC
VEGF-D GGTGCTGAATGAGATCTCCC GCAAGACGAGACTCCACTGC
Total RAGE ACTACCGAGTCCGAGTCTACC GTAGCTTCCCTCAGACACACA
RAGE variant 1 AAGCCCTCCTGTCAGCATCAG GGCCATCACACAGGCTCGAT
RAGE variant 3 ACCCACCCTAGCCACGGAC GTCCCCCGGCACCATTCTC
ADAM10 AATCCAAAGTTGCCTCCTCCTAA GGGTTGCTGAATGGGCTGT
GLO1 ATGACGAGACTCAGAGTTAC
CACAA
TAGACATCAGGAACGGCAAA
TCC
OST-48 (AGE R1) CCCCTTCGTGAGGACCTTCCT CGTCAGGCAGCTTGAACTGGA
80 K-H (AGE R2) TCTACCGGCTTTGCCCCTTC CTTGTCATGATCAGGGCCAGC
Galectin-3 (AGE
R3)
TTATGGTGTCCCCGCTGGAC AGGCAAGGGCAGGTCATAGGG
RPL13a CCTGGAGGAGAAGAGGAAAG
AGA
TTGAGGACCTCTGTGTATTTGT
CAA
Human
Total RAGE AACACCAGCCGTGTGAGTTCA CCGAGTCCGTGTCTACCAGAT
esRAGE GGCCAACTGCAGGTGAG TTTTCTGGGGCCTTCCATTC
RPL13a CCTGGAGGAGAAGAGGAAAG
AGA
TTGAGGACCTCTTGTGTATTTG
TCAA
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also shown in ARDS, a disease associated with damage to the ATI cell,
but here in the absence of expression changes [23,24]. Plasma levels of
sRAGE were found to be affected as well in COPD and ARDS, albeit
in COPD in the opposite direction as at the local level [15,23]. Plasma
sRAGE measurements are currently receiving ample attention as a po-
tential biomarker of disease in general and of lung damage in particular.
Systemic hypoxia is a consequence of a number of pulmonary dis-
eases. Links between RAGE and oxygen levels are evident from a study
that showed enhanced RAGE expression in lung tissue by hyperoxia
and protection from hyperoxia-induced inﬂammation, injury and mor-
tality in RAGE deﬁcient mice compared to wild type mice [25]. Further-
more, in our studies patients with COPD treated with oxygen displayed
lower plasma sRAGE levels compared to patients not receiving this
treatment [15,26]. In contrast to enhanced pulmonary RAGE expression
in response to hyperoxia, it is unknown if hypoxia inﬂuences lung RAGE
expression, and if this might reﬂect in alterations in circulating sRAGE
levels. Understanding the effect of different insults on RAGE expression
in lung tissue is important, given the fact that RAGE plays an important
role in pulmonary physiology as well as pathophysiology. Moreover,
plasma levels of sRAGE are considered biomarkers in various pulmonary
conditions. A recent study furthermore showed that acute hypoxia
induced the generation of AGEs by endothelial cells, which by engage-
ment with RAGE elicited tissue injury [27].
The present study thus investigated the effect of chronic hypoxia on
plasma sRAGE levels and the expression of RAGE, its splice variants and
sheddases as well as on the accumulation of AGEs in lung tissue of mice.
2. Materials and methods
2.1. Animal handling and treatment
Fifty-two week old male C57BL/6J mice (Charles River Laboratories)
were exposed to ambient air (normoxia, n = 8) or chronic hypoxia
(n= 8) for 21 days. Mice of this age were used as it is a more relevant
age to study the effects of hypoxia in relation to lung diseases which
occur at middle to advanced age in humans. All mice were housed in
experimental chambers at 21 °C with a 12-h dark/light cycle. Mice
received standard chow (V1534–000 ssniff R/M-H, ssniff Spezialdiäten,
Soest, Germany) and water ad libitum. Using the proOX P110
(BioSpherix, Lacona, NY, USA) system, O2 was replaced by N2 in a
stepwise manner to create normobaric oxygen levels of 12% (day 1),
10% (day 2), and ﬁnally 8% (60.8 mm Hg) on day 3. The later oxygen
concentration was maintained until day 21. Three to four mice were
housed per cage. Daily food intake was determined per cage, and mice
were weighed daily. On day 21, micewere anesthetized with isoﬂurane
gas, the abdominal cavity was opened and aortic blood was collected
into a heparin-coated 1 ml syringe (Becton Dickinson, Breda, The
Netherlands). Blood gas and pH were measured immediately using
the ABL 510 Blood Gas Analyzer (Radiometer; Diamond Diagnostics,
Holliston, MA) and blood cell count was determined with the Coulter
Ac T Diff hematology Analyzer (Beckman Coulter, Woerden, The
Netherlands). Plasma was stored at−80 °C until further analyses. The
lungs were snap frozen in liquid nitrogen and stored immediately at
−80 °C. The protocol was approved by the Committee for Animal
Care and Use of Maastricht University (project 2009-151).
2.2. Quantitative polymerase chain reaction
RNA from total lung tissue was isolated using the RNeasy Mini kit
(Qiagen, CA, USA) and form cells using the High Pure RNA isolation
kit (Roche). An equal amount of RNA was reverse transcribed to
cDNA using the transcriptor cDNA synthesis kit (Roche Applied Sci-
ences, Mannheim, Germany). PCR reactions were performed on an
ABI 7900HT real time PCR (ABI 7900HT, Applied Biosystems, Foster
City, CA, USA) using Power SYBR® Green PCR Master Mix (AppliedBiosystems) and primers listed in Table 1. Relative mRNA expression
was calculated using the ΔΔctmethod with RPL13a as reference gene.
2.3. Western blot
Lung tissue was lysed in 1× RIPA buffer (Cell Signaling Technology,
Denver, MA, USA) and the total protein content was determined with
the DC protein kit (BIO-RAD Laboratories Inc., Hercules, CA, USA).
Equal amounts of protein were separated on 4–12% SDS PAGE gels,
and transferred to a nitrocellulose membrane. The membrane was
blocked with 5% nonfat milk in Tris Buffered Saline (TBS) containing
0.1% tween (T), at room temperature (RT) for 1 h. Membranes were
then incubated overnight with primary antibodies raised against
RAGE (1:1000, H300, Santa Cruz Biotechnology, Santa Cruz, CA, USA),
ADAM10 (1:1000, generous gift from S. Rose-John, Christian-
Albrechts-University), HMGB1 (1:2500, Cell Signaling Technology) or
GAPDH (1:2500, Cell Signaling Technology) in 1% milk dissolved in
TBST. Blots were washed 3 timeswith TBST, and incubatedwith respec-
tive peroxidase-conjugated secondary antibodies at RT for 1 h. After 3
washes with TBST, conjugated peroxidase was detected by chemilumi-
nescence using the Pierce ECL Western blotting substrate (Thermo sci-
entiﬁc, Rockford, IL, USA). Densitometric quantitation of Western blots
was performed using Quantity One software (BIO-RAD Laboratories).
2.4. Gelatinase activity assay
0.5 mg of protein containing RIPA buffer lung lysate was used from
each animal for the measurement of gelatinase activity using the
gelatinase assay kit according to the manufacturer's instructions (Enz
check, Life Technologies, Leusden, NL).
2.5. Determination of advanced glycation end products
Insoluble lung proteins (IP) were prepared by homogenization in
Chelex-100 (Bio-Rad) treated PBS followed by extraction with each of
2:1 chloroform-methanol, 1 M sodium chloride, 0.5 M acetic acid and
5 μg pepsin/ml 0.5 M acetic acid as previously described for skin
(Sell et al., Proc. Natl. Acad. Sci., 93:485–490, 1996). Hemewas removed
by the procedure of Chang et al. [59] and each pellet was freeze-dried.
Approximately 2 mg portion of each IP preparation was enzymatically
digested into free amino acids by sequential digestion at 37 °C for 24 h
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collagenase (Type VII, Sigma), 0.7 units pronase (Roche), 1 unit entero-
kinase (Sigma) and 5 units prolidase (Sigma). The protein content of
each digest was determined by the ninhydrin assay assuming 1 mg
protein≈ 10 μmol leucine equivalents [60]. Each digest ~100 μg protein
was spiked with isotopically-labeled internal standards and analyzed
(~40 μg) by high pressure liquid chromatography–mass spectrometry
(HPLC–MS/MS) as previously described [61] for glyoxal (G-H1) and
methylglyoxal (MG-H1) hydroimidazolones, fructose-lysine (FL),
carboxymethyl-lysine (CML) and carboxyethyl-lysine (CEL). Long
wavelength ﬂuorophore (LW-1) was assayed by HPLC with ﬂuores-
cence detection as previously described [28].2.6. ELISA
Plasma sRAGE levels were determined by amouse speciﬁc sandwich
ELISA from R&D systems (Minneapolis, MN, USA) according to the
manufacturer's instructions.2.7. Cell culture
A549 cells with stable knockdown of Hif1α or control were used as
described previously [29].2.8. Statistical analysis
Data were analyzed using the Mann–Whitney U test (SPSS 19) and
were expressed as mean ± SD. Differences were considered signiﬁcant
if p b 0.05.3. Results
3.1. Blood gas and hematologic adaptations induced by exposure to chronic
hypoxia
Table 2 summarizes the results of the blood gas analyses and the he-
matological proﬁle from mice exposed to chronic hypoxia compared to
normoxia. As expected, PaO2 and SaO2 were signiﬁcantly decreased in
hypoxia compared to normoxia exposedmice.Mice exposed to hypoxia
exhibited a lower blood pH and a lower HCO3 concentration, but a nor-
mal PaCO2 level. Furthermore, the hematocrit, hemoglobin concentra-
tion, erythrocyte count and mean corpuscular volume were found to
be signiﬁcantly increased in mice exposed to chronic hypoxia. Some of
these data have been published previously [30].Table 2
Overview of blood analyses of normoxia and hypoxia exposed mice.
Normoxia (n = 8) Hypoxia (n = 6) p-value
Arterial blood gas analyses
pH 7.3 (0.03) 7.1 (0.06) b0.001
PaO2, mm Hg 128.2 (8.4) 34.1 (3.9) b0.001
PaCO2, mm Hg 35.4 (3.7) 35.8 (3.1) 0.90
HCO3, mmol/L 15.9 (2.2) 11.3 (1.8) b0.001
SaO2, % 100.6 (0.9) 24.3 (5.8) b0.001
Hematological adaptations
Hematocrit, % 0.45 (0.03) 0.76 (0.16) b0.001
Hemoglobin, mmol/L 9.0 (0.6) 14.6 (0.3) b0.001
Erythrocytes, ×106 10.0 (0.6) 13.6 (0.4) b0.001
MCV, fL 45.5 (0.70) 56.3 (1.8) b0.001
MCH, pg 0.91 (0.18) 1.08 (0.04) b0.001
MCHC, g/dl 19.8 (0.43) 19.1 (0.7) 0.028
Data expressed as mean ± SD. Abbreviations: MCV: mean corpuscular volume; MCH:
mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration.3.2. Upregulation of pulmonary expression of VEGFs
In addition to the hematological adaptations, we assessed whether
hypoxia affected the lungs of mice in our model. As expected, chronic
hypoxia induced gene expression of vascular endothelial growth factor
(VEGF)-A, a hypoxia-inducible gene. Also VEGF-D expressionwas signif-
icantly enhanced in response to hypoxia and for VEGF-B a trend to
increase was observed. Interestingly, VEGF-Cwas found to be downreg-
ulated in lung tissue upon chronic hypoxia exposure (Fig. 1).3.3. Hypoxia associated alterations in pulmonary RAGE expression
Wenext assessed the impact of chronic hypoxia exposure on pulmo-
nary expression of RAGE and its variants at themRNA and protein level.
As shown in Fig. 2, gene expression of total RAGE was signiﬁcantly
enhanced in mice exposed to hypoxia compared to mice at normoxia.
Furthermore, RAGE splice variants 1 and 3 which translate into an
endogenous soluble protein capable of scavenging RAGE ligands were
examined. As for total RAGE, signiﬁcantly increased mRNA levels of
variants 1 and 3 were observed in hypoxia exposed mice.
In contrast, at the protein level signiﬁcantly decreased levels of both
mRAGE and sRAGEwere found byWestern blotting in hypoxia exposed
mice (Fig. 3A and B). Furthermore, the ratio of soluble to membrane
RAGE was signiﬁcantly enhanced in response to hypoxia (Fig. 3C).3.4. No role for HIF1α in the regulation of RAGE mRNA expression in vitro
To assess whether HIF1α is implicated in the regulation of RAGE
mRNA expression at baseline and in response to hypoxia, A549, alveolar
epithelial type II cells with stable knockdown of HIF1α were treated
with the hypoxia mimetic CoCl for 48 h and gene expression of RAGE
was analyzed. A similar dose of CoCl was found to lead to a similar in-
duction of HIF1α protein levels as culture of A549 cells under 1% O2
[31]. First, this model of acute hypoxia in vitro caused a downregulation
of total RAGE as well as esRAGE gene expression. Secondly, knockdown
of HIF1α did not affect basal expression of RAGE or its soluble transcript
variant and it did not modulate the effects of CoCl (Fig. 4).3.5. Chronic hypoxia increases circulating sRAGE levels
In some pulmonary diseases plasma levels of sRAGE are altered and
could serve as biomarkers because of their correlation with lung func-
tion. We thus assessed here whether chronic hypoxia affected plasma
sRAGE levels. As shown in Fig. 5A, chronic hypoxia signiﬁcantly en-
hanced sRAGE levels in plasma of hypoxia treated mice compared to
mice at normoxia (normoxia: 132.0 ± 82.4; hypoxia: 571.4 ± 774.0;
pg/ml; p=0.021). Furthermore, a negative association between plasma
sRAGE and lung sRAGE was observed (r =−0.597, p= 0.03, Fig. 5B).Fig. 1.Chronic hypoxia-induced changes inVEGF gene expression.VEGF-A,VEGF-B,VEGF-D
and VEGF-C mRNA levels were analyzed by QPCR and data expressed as mean relative
gene expression corrected for RPL13a ± SD; normoxia n = 8, hypoxia n = 7; the
Mann–Whitney U test was used for statistical analyses.
Fig. 2. Signiﬁcant increases in gene expression of RAGE and its variants 1 and 3 in lungs of
hypoxia exposedmice. Data are expressed as mean relative gene expression corrected for
RPL13a± SD; normoxia n = 8, hypoxia n = 7; the Mann–Whitney U test was used for
statistical analyses.
Fig. 4.No role for HIF1α in the decreasedmRNA expression of total and esRAGE after CoCl
treatment in vitro. A549 cells stably transfectedwith shRNAagainst HIF1α or control were
treated with 200 μM CoCl for 48 h after which gene expression of total and esRAGE were
determined by QPCR corrected for RPL13a.
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Although the relative amount of sRAGE was increased in lung tissue
of hypoxia exposed mice, the net amount of sRAGE decreased. Because
these observations are likely not explained by the increased mRNA
expression of variants 1 and 3, we analyzed whether hypoxia affected
shedding through effects on MMP9 and ADAM10 in total lung tissue.Fig. 3. Decreased membrane and soluble RAGE protein levels in lung tissue of mice ex-
posed to chronic hypoxia. A) Representative Western blots of mRAGE and sRAGE on
lung tissue lysates. B) Quantiﬁcation of mRAGE and sRAGE signals on Western blot,
using GAPDH as a loading control. Data are expressed as mean arbitrary units ± SD;
normoxia n = 8, hypoxia n = 5. C) Ratio of sRAGE to mRAGE expression from (B). The
Mann–Whitney U test was used for statistical analyses.Hypoxia exposed mice showed a trend to increased ADAM10 mRNA
levels compared to mice at normoxia (Fig. 5A). Furthermore protein
levels of the 100 kDa pro-form of ADAM10were found to be signiﬁcant-
ly enhanced in hypoxia treated mice, whereas the 64 kDa active form
was found to be downregulated (Fig. 5B and C). Since both the net
amount of active ADAM10 and the ratio of active to pro-ADAM10
(Fig. 5D) are signiﬁcantly decreased after chronic exposure to hypoxia,
it is unlikely that elevated soluble RAGE levels are due to enhanced
cleavage of the membrane form by this sheddase. Furthermore, we an-
alyzed total lung tissue gelatinase activity as mRNA expression of
MMP9, another important sheddase, was too low to obtain reliable
data (data not shown). Results in Fig. 6E show that chronic hypoxia
did not signiﬁcantly affect lung gelatinase activity.Fig. 5. Hypoxia induces signiﬁcant increases in plasma sRAGE levels (A), which shows a
negative association with lung lysate sRAGE (B). Data are expressed as mean ± SD and
Spearman rho correlation coefﬁcient respectively; normoxia n = 8, hypoxia n = 7.
Fig. 6. Effects of chronic hypoxia on RAGE sheddase ADAM10 and gelatinase activity. A) Trend of increased ADAM10 gene expression in hypoxia exposedmice. Data are expressed asmean
relative gene expression corrected for RPL13a ± SD; normoxia n = 8, hypoxia n = 7. B) Representative Western blots for pro ADAM10 and active ADAM10 on lung tissue lysates.
C) Quantiﬁcation of pro ADAM10 and active ADAM10 fromWestern blot, using GAPDH as an internal control. Data are expressed asmean arbitrary units ± SD; normoxia n= 8, hypoxia
n= 5; theMann–Whitney U test was used for statistical analyses. D) Ratio of active to pro ADAM10 from (C). E). Gelatinase activity was assessed in whole lung lysates and expressed as
units/mg protein; normoxia n = 8, hypoxia n = 7; the Mann–Whitney U test was used for statistical analyses.
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hypoxia
The observed alterations in RAGE homeostasis in mice exposed to
chronic hypoxia could, next to direct effects of hypoxia on expression
of RAGE and sheddases, be associated with differential levels of RAGE
ligands. We thus analyzed the major pulmonary RAGE ligand HMGB1,
and found that chronic hypoxia markedly attenuated HMGB1 protein
levels (Fig. 7A and B). Secondly, we analyzed a panel of AGEs including
GH1, MGH1, FL, CML, CEL, and LW1 in the insoluble protein fraction of
lung tissue of both mouse groups. As indicated in Fig. 7C–H, chronic
hypoxia only signiﬁcantly enhanced LW1 levels.This observation led us to further investigate AGE detoxifying
mechanisms, which could have limited accumulation of AGEs. No
effect of hypoxia on the AGE detoxifying enzyme glyoxalase 1 was
observed in Fig. 8A. We also examined the inﬂuence of chronic hypoxia
on the expression levels of receptors which bind and remove AGEs.
80 K-H/AGER2 and galactin-3/AGER3 were found to be signiﬁcantly
increased in the hypoxia compared to the normoxia exposed mouse
group (p=0.048, p=0.002 respectively). The lack of effect of hypoxia
on oligosaccharyl transferase (OST)-48/AGER1 expression was likely
due to the large variability (Fig. 8B). Furthermore, based on the average
CT values of these three AGERs under normoxic conditions it appears
that AGER1 is the most abundantly expressed at the mRNA level in
Fig. 7. Fluorescent AGE LW-1 was selectively increased by hypoxia in lung tissue matrix. A) Representative Western blots for HMGB1 on lung tissue lysates. B) Quantiﬁcation of HMGB1
fromWestern blot, using GAPDH as an internal control; normoxia n=8, hypoxia n=7; theMann–WhitneyU test was used for statistical analyses. Insoluble lung AGEs C) GH1, D)MGH1,
E) FL, F) CML, G) CEL and H) LW1 levels expressed as mean ± SD; normoxia n = 8, hypoxia n = 8; the Mann–Whitney U test was used for statistical analyses.
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0.52; AGER3 25.12 ± 0.56, average SD).
4. Discussion
Chronic hypoxia was shown to decrease lung protein levels of both
mRAGE and sRAGE, with an increased sRAGE to mRAGE ratio. These
alterations were accompanied by increased mRNA expression of 2 iso-
forms that code for soluble RAGE, but also by decreased protein levels
of the active form of the sheddase ADAM10. Hypoxia furthermore in-
creased plasma sRAGE concentrations, which negatively correlated
with pulmonary sRAGE levels. Although these alterations in the lungs
and plasma are in opposing directions, indicating that plasma sRAGElevels are not a reﬂection of sRAGE alterations in the lungs, the signiﬁ-
cant correlation between both compartments hints at a commonmech-
anism behind the observed effects in the respective compartments.
Only the AGE LW1 was found to be increased in lung tissue by chronic
hypoxia. The enhanced gene expression of AGE receptors 2 and 3 in re-
sponse to chronic hypoxia could explain the absence of accumulation of
other AGEs investigated.
Chronic hypoxia treatment induced hypoxemia in blood which was
evidenced by the decreased levels of oxygen tension and saturation, de-
creased pH and compensatory increase in the RBC numbers and param-
eters in hypoxia exposed mice. In addition, local effects of hypoxia in
lung tissue were evidenced by the upregulation of VEGF-A, a hypoxia
sensitive gene. In the present study we also examined the effect of
Fig. 8. Chronic hypoxic induced AGER2 and AGER3 expression, but did not affect GLO1, or
AGER1 gene expression. A) GLO1, B) AGER1, AGER2 and AGER3 mRNA expression repre-
sented as mean relative gene expression corrected for RPL13a ± SD; normoxia n = 8,
hypoxia n = 7; the Mann–Whitney U test was used for statistical analyses.
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structural features, but display different biological activities [32]. The
biological function of VEGF-B is similar to that of VEGF-A, but as reported
is not signiﬁcantly inﬂuenced by hypoxia. The absence of a signiﬁcant
difference in VEGF-B gene expression between hypoxia and normoxia
exposed mice is in line with this literature [33]. VEGF-C and VEGF-D
on the other hand control the growth of lymphatic vessel in lungs [34,
35]. Although hypoxia has been shown not to induce VEGF-C [33] we
here observed decreased VEGF-C expression. Effects of hypoxia on
VEGF-D have not been reported, but an induction was evident in our
study. The overall effects of hypoxia on pulmonary lymphatic vessels
and the role of these 2 VEGF isoforms herein remain to be investigated.
HIF1-α is the main molecular effector of hypoxia signaling. It has
been shown that HIF1-α is able to bind the HIF-1α binding site present
in theRAGEpromoter region and activate gene transcription [36]. In line
herewith we observed up-regulated gene expression of RAGE as well as
its splice variants that code for soluble forms by chronic hypoxia in mu-
rine lung tissue. In vitro, a model of acute hypoxia in contrast attenuated
total and esRAGE gene expression in a cancer-derived lung epithelial
cell line, and we did not ﬁnd evidence for a role of HIF1α herein. A
study in pancreatic tumor cells also found RAGE expression not to be
modulated by HIF1α in response to hypoxia, but instead identiﬁed a
role for NF-κB [37], for which a binding site in the RAGE promotor is
present as well.
In contrast to the mRNA data however, downregulation of mRAGE
and sRAGE protein levels were found in lung tissue ofmice after chronic
exposure to hypoxia in the current study. We did unfortunately not
collect lung tissue for immunohistochemical localization of RAGE and
the existing literature on effects of acute hypoxia on RAGE expression
in lung tissue did also not examine in which compartments it was
altered. In human IPF samples RAGE protein levels were reported to
be attenuated, which was associated with weaker staining in bronchial
and alveolar epithelium, as well as ﬁbroblasts [38]. In COPD and ciga-
rette smoke exposed mice on the other hand, enhanced RAGE protein
levels were mainly derived from increased expression in alveolarepithelium [21,39]. It remains to be examined if chronic hypoxia causes
a homogenous downregulation of RAGE protein levels in the lungs, or
whether this is conﬁned to alveolar regions.
Attenuated rates of translation, decreased protein stability or en-
hanced receptor turnover are possible mechanisms that could underlie
the discrepancy betweenmRNA and protein expression. Regardless, the
ratio of sRAGE to mRAGE was signiﬁcantly enhanced in lung tissue, as
were sRAGE levels in the circulation of hypoxia treated mice compared
to mice under normoxia. The increased mRNA expression of variants 1
and 3 could likely not explain the relative increase in sRAGE since the
net amount of pulmonary sRAGE protein was decreased. We therefore
speculated that hypoxia might have activated sheddases. Two possible
mechanisms causing shedding of membrane RAGE have been reported.
One is by sheddases includingMMP9 and ADAM10 [40]; the other is by
G-protein coupled receptor mediated shedding [41]. In the present
studymRNAexpression and levels of inactive pro-ADAM10were upreg-
ulated,whereas protein levels of the active form of the enzymewere de-
creased by hypoxia. It is therefore unlikely that the relative increase in
sRAGE levels is due to ADAM10-mediated shedding. Unfortunately ef-
fects of hypoxia on MMP9 speciﬁcally could not be assessed in the cur-
rent study because expression levels were below the detection limit.
Total lung gelatinase activity was on the other hand not affected by
chronic hypoxia, data which are in linewith a study reporting no signif-
icant effect onMMP9 gene and protein expression by chronic hypobaric
hypoxia [42]. To exclude a role for shedding, other sheddases remain to
be investigated.
Enhanced sRAGE levels could also be a reﬂection of mere damage to
pneumocytes. Indeed, acute hypoxia, 7% O2 for 6 h, induced a slight in-
crease in sRAGE levels in the BALF, which was shown to be due to dam-
age to type I pneumocytes [43]. Hyperoxia treatment on the other hand
has also been shown to lead to increased pulmonary and BALF sRAGE
levels. The enhanced BALF and plasma sRAGE levels inmodels of hypox-
ia aswell as hyperoxiaﬁt with the proposed role of sRAGE as amarker of
pneumocyte damage, as both models are associated with alveolar dam-
age. Unfortunately, we did not collect BALF to measure sRAGE in the
present study.
In addition to the potential role of sRAGE as a damage marker, the
observed alterations in RAGE homeostasis in response to chronic
hypoxia are likely to play a functional role in oxygen sensing and adap-
tation to varied oxygen levels. This is indeed not only implied by its
localization to the basolateral side of type I cells and thereby a role in
cell spreading, thinning and adherence, but also by the observed protec-
tion from hyperoxia-induced inﬂammation, damage and mortality in
RAGE knock-out mice [25]. It is proposed that the absence of RAGE
limits both the induction and ampliﬁcation of inﬂammatory responses
otherwise induced by themultitude of ligands. Furthermore the protec-
tion offered by exogenous administration of sRAGE inmodels of lung is-
chemia–reperfusion injury [44], as well as hypoxia [45] indicates that
the RAGE alterations observed in ourmodel could be part of an adaptive
and protective response mechanism to chronic hypoxia. Studies aimed
at further unraveling this hypothesismight have to distinguish between
the function of RAGE as an adhesion molecule in alveolar regions vs its
function as pattern recognition receptor in airways. In this regard,
HMGB1, a RAGE ligand acting as a danger signal, has been shown to
be an early mediator of the response to acute hypoxia/ischemia [46].
HMGB1 was furthermore found to be implicated in the pathogenesis
of pulmonary arterial hypertension using amousemodel of 2 day expo-
sure to 10% O2. This study demonstrated enhanced levels of HMGB1 in
lung lysates as well as BALF [47]. In our model of chronic hypoxia on
the other hand, we found lower levels of HMGB1 in lung lysates,
which again could represent an adaptive mechanism, which might be
linked to the lower levels of RAGE. It remains to be investigatedwhether
BALF levels of HMGB1 are attenuated as well.
For several years it has been known that high blood glucose concen-
trations promote the formation of AGEs, intra- as well as extracellularly
[48]. In addition, high dietary intake of AGEs enhances organ AGE levels
999P. Gopal et al. / Biochimica et Biophysica Acta 1852 (2015) 992–1000as well RAGE expression, including in lung tissue [49–51]. Oxidative
stress and inﬂammation may also play a role in the formation of AGEs
in vivo through a glucose independent pathway [52,53]. Although
hypoxia induces oxidative stress in several organs including lungs [54]
and induction of AGEs has been observed by ischemia/reperfusion
injury in the heart [55–57], neither glycoxidation nor lipoxidation, as
reﬂected by CML and CEL levels, were increased. Similarly, no changes
in the levels of hydroimidazolones MGH1 and GH1 were observed,
implying no effect of hypoxia on methylglyoxal and glyoxal levels,
respectively. Also, furosine levels were unchanged, thereby reﬂecting
no impact of hypoxia on glucose levels and protein glycation by glucose.
The lack of accumulation of the other AGEs investigated was likely
not due to compensatory enzymatic detoxiﬁcation since GLO1 expres-
sion was not found to be affected by hypoxia. On the other hand,
mRNA expression of AGER2 and AGER3, two receptors which are
involved in the detoxiﬁcation and removal of AGEs was induced in
lung tissue by chronic hypoxia.
We investigated the effect of the same hypoxia regimen in mice of
12weeks of age on certain, but not all parameters reported in this man-
uscript. RAGE and ADAM10 data were in agreement with the older
mice, but in these younger mice, despite attenuated GLO-1 mRNA ex-
pression in response to chronic hypoxia, none of the AGEs investigated
was increased, including LW-1 (data not shown). In older mice howev-
er, a novel ﬁnding ofmajor interest is that the lung ﬂuorescent AGE LW-
1 levelwas speciﬁcally and signiﬁcantly increased by hypoxia. The ratio-
nale for determining LW1 in this study was to test the hypothesis that
hypoxia would increase its levels. This hypothesis grew out from previ-
ous observations where LW1 levels were found elevated in insoluble
collagen of skin obtained at autopsy from non-diabetic individuals suf-
fering from chronic lung disease [28,58]. Nomechanism in its formation
can be currently inferred based upon LW1 structure of which we only
know that it includes an aromatic ring coupled to a lysine residue and
a sugar of undetermined nature. Thus, this study independently and
for the ﬁrst time conﬁrms the suggested role of hypoxia in LW-1
formation.
In summary, chronic hypoxia is associated with downregulation of
pulmonary RAGE protein levels, but a relative increase in sRAGE,
which is reﬂected in increased plasma sRAGE levels. These alterations
might be part of the adaptive and protective response mechanism to
chronic hypoxia and do not appear to be associated with AGEs forma-
tion, except for the ﬂuorescent AGE LW-1 which emerges as a novel tis-
sue marker of hypoxia.
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